Login

Switch On Your HIV Smarts.

Capping Coinsurance Payments for PrEP and HIV Meds

Capping Coinsurance Payments for PrEP and HIV Meds

, by Emily Newman

Covered California will soon vote on capping the amount consumers have to pay for drugs in the “specialty” tier. Two experts explain what this will mean for people paying for HIV medications and Truvada for PrEP. Read More

DHHS: Atripla No Longer Recommended as First-Line HIV Therapy

DHHS: Atripla No Longer Recommended as First-Line HIV Therapy

, by Emily Newman

The U.S. Department of Health and Human Services recently demoted the widely-used HIV combination pill Atripla from first-line HIV therapy recommendations, not because of a problem with the drug itself, but because of the changing landscape in HIV treatment. Read More

Meth, Crack, Coke & Ecstasy: Effects on HIV Disease Progression

Meth, Crack, Coke & Ecstasy: Effects on HIV Disease Progression

, by Emily Newman

For the first time, a study investigates whether stimulants lead to poorer health outcomes for people with HIV—independent of antiretroviral use. Read More

An “Improved Backbone” for New HIV Regimens Now Under FDA Review

An “Improved Backbone” for New HIV Regimens Now Under FDA Review

, by Emily Newman

A new version of tenofovir may result in a better-tolerated replacement for Truvada. Read More

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

, by Emily Newman

An integrase inhibitor fared well in a head-to-head comparison with a protease inhibitor regimen for people just starting ART. Find out why this is surprising and what it could mean for treatment naïve people with high viral loads. Read More